Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Prestina Smith-DavidsonSinonasal and Olfaction Program, National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, Bethesda, Maryland, U.S.A.ORCID 0000-0001-5673-3279
Khaled AltartoorDepartment of Otolaryngology - Head and Neck Surgery, Emory University School of Medicine, Emory University, Atlanta, Georgia, U.S.A.
M M KabongoSinonasal and Olfaction Program, National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, Bethesda, Maryland, U.S.A.ORCID 0000-0002-5158-6860
Henry ClaussenEmory Integrated Computational Core, Emory University, Atlanta, Georgia, U.S.A.
Robert A ArthurEmory Integrated Computational Core, Emory University, Atlanta, Georgia, U.S.A.ORCID 0000-0003-4824-4971
H R JohnstonEmory Integrated Computational Core, Emory University, Atlanta, Georgia, U.S.A.ORCID 0000-0001-5668-1093
John M DelGaudioDepartment of Otolaryngology - Head and Neck Surgery, Emory University School of Medicine, Emory University, Atlanta, Georgia, U.S.A.
Sarah K WiseDepartment of Otolaryngology - Head and Neck Surgery, Emory University School of Medicine, Emory University, Atlanta, Georgia, U.S.A.
C A SolaresDepartment of Otolaryngology - Head and Neck Surgery, Emory University School of Medicine, Emory University, Atlanta, Georgia, U.S.A.
Emily M BarrowDepartment of Otolaryngology - Head and Neck Surgery, Emory University School of Medicine, Emory University, Atlanta, Georgia, U.S.A.
Kelly R MaglioccaDepartment of Pathology and Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia, U.S.A.
Michael KovalDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University School of Medicine, Atlanta, Georgia, U.S.A.ORCID 0000-0002-5422-5614
Joshua M LevySinonasal and Olfaction Program, National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, Bethesda, Maryland, U.S.A.ORCID 0000-0001-5907-3421
Funding
Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Ragini Reiney Kudchadkar · 2009 to 2026
$47.5M
Sinonasal and Olfaction ProgramZIADC000098 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI LEVY, JOSHUA · 2024 to 2025
$2.5M
Regulation of epithelial function using targeted nanowiresR01HL158979 · NHLBI · EMORY UNIVERSITY · PI DESAI, TEJAL A., KOVAL, MICHAEL H. · 2022 to 2025
$2.5M
Endogenous Cannabinoids in Inflammatory Airway DiseaseR03TR004022 · NCATS · EMORY UNIVERSITY · PI LEVY, JOSHUA M · 2022 to 2023
$157k
OLFACTORY CONTROL OF A LOCOMOTORY NEURAL NETWORKF32DC000097 · NIDCD · UNIVERSITY OF ARIZONA · PI WOOD, DEBRA E · 1992 to 1995
objectivesAllergic fungal rhinosinusitis (AFRS) is an eosinophilic subtype of chronic rhinosinusitis with nasal polyposis (CRSwNP). This study aimed to investigate the transcriptome of AFRS nasal polyp epithelium.
methodsSinonasal epithelial cells were harvested from healthy nasal mucosa and polyp tissue collected from participants undergoing elective sinonasal surgery. Primary epithelial cells were subsequently grown in air/liquid interface and subjected to RNA-seq analysis, RT-qPCR, immunoblotting, and immunostaining.
resultsA total of 19 genes were differentially expressed between healthy and AFRS sample epithelium. The second top candidate gene, ranked by adjusted p-value, was prostaglandin E receptor 2 (PTGER2). The upregulation of PTGER2 was confirmed by RT-qPCR and immunoblot. The presence of the EP2 receptor, encoded by the PTGER2 gene, was confirmed by immunocytochemistry.
conclusionPTGER2 is a potential novel therapeutic target for AFRS. EP2 dysregulation is associated with aspirin-exacerbated respiratory disease, potentially giving insight into common mechanisms of disease in severe CRSwNP. LEVEL OF EVIDENCE: NA Laryngoscope, 135:S1-S8, 2025.
Indexed as
MycosesNasal MucosaNasal PolypsReceptors, Prostaglandin E, EP2 SubtypeRhinitis, AllergicSinusitisAdultAllergic Fungal SinusitisEpithelial CellsFemaleHumansMaleMiddle AgedPTGER2 protein, humanReceptors, Prostaglandin E, EP2 Subtypeallergic fungal sinusitiseicosanoid receptornasal polyposisprostaglandin E receptors
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Prostaglandin E Receptor 2 (EP2) Dysregulation in Allergic Fungal Rhinosinusitis Nasal Polyp Epithelium. · full record | OpenQuestion